Efficacy and safety of ezetimibe coadministered with statins: Randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia

International Journal of Clinical Practice

Volumn 58, Issue 8, 2004, Pages 746-755

  Davidson, Michael H ^a   Ballantyne, C M ^b   Kerzner, B ^c   Melani, L ^d   Sager, P T ^e   Lipka, L ^e   Strony, J ^e   Suresh, R ^e   Veltri, E ^e  

^a RADIANT RESEARCH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Health Trends Research   (United States)

^d Menarini Ricerche SpA   (Italy)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cholesterol absorption inhibitor; Coadministration; Ezetimibe; Hypercholesterolemia; LDL cholesterol; Statin

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 4544250506     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00289.x     Document Type: Article

References (22)

1. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1-S10.
2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
3. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
4. Fruchart J-C, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998; 81: 912-7.
5. Backman JT, Kyrklund C, Kivistö KT et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-9.
6. Federman DG, Hussain F, Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 2001; 94: 1023-6.
7. Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998; 19: 355-71.
8. van Heek M, France CF, Compton DS et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283: 157-63.
9. van Heek M, Farley C, Compton DS et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000; 129: 1748-54.
10. Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729-41.
11. Knopp RH, Dujovne CA, Le Beaut A et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003; 57: 363-8.
12. Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91: 418-24.
13. Melani L, Mills R, Hassman D et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003; 24: 717-28.
14. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-34.
15. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-15.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
17. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23.
18. Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000; 85: 15E-9E.
19. Davidson MH, Dillon MA, Gordon B et al. Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159: 1893-900.
20. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000; 23: 197-213.
21. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22: 441-57.
22. Pearson TA, Laurora I, Chu H et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.